Market Summary
USD45.78+0.15
Market Closed0.33%
CTLT Alerts
CTLT Stock Price
CTLT RSI Chart
CTLT Valuation
CTLT Price/Sales (Trailing)
CTLT Profitability
CTLT Fundamentals
CTLT Revenue
CTLT Earnings
Price Action
52 Week Range
31.4581.72
(Low)(High)
Last 7 days
-4.0%
Last 30 days
1.7%
Last 90 days
13.1%
Trailing 12 Months
-38.9%
CTLT Financial Health
CTLT Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for CTLT
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-09-10 | Barg Steven | acquired | - | - | 718 | - |
2023-08-31 | Ryan Michelle R | bought | 49,980 | 49.98 | 1,000 | - |
2023-08-30 | GREISCH JOHN J | bought | 1,055,040 | 50.24 | 21,000 | executive chair |
2023-08-28 | Ryan Michelle R | acquired | - | - | 979 | - |
2023-08-28 | DAMELIO FRANK A | acquired | - | - | 979 | - |
2023-08-28 | Okey Stephanie | acquired | - | - | 979 | - |
2023-08-24 | Gennadios Aristippos | sold | -17,618 | 44.49 | -396 | group pres. pharma & consumer |
2023-08-24 | Carletti Lorenzo | sold | -9,657 | 44.71 | -216 | svp global ops ph & cons hlth |
2023-08-24 | Pravda Ricardo | sold | -16,854 | 44.47 | -379 | chief transformation officer |
2023-08-24 | Grippo Michael J | sold | -17,355 | 44.5 | -390 | svp, strategy & corp. dev. |
Which funds bought or sold CTLT recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-26 | BROOKFIELD Corp /ON/ | sold off | -100 | -720,116 | - | -% |
2023-09-21 | Baystate Wealth Management LLC | unchanged | - | -2,079 | 4,032 | -% |
2023-09-20 | BARCLAYS PLC | added | 606 | 115,299,000 | 146,802,000 | 0.09% |
2023-09-12 | Farther Finance Advisors, LLC | reduced | -35.00 | -6,005 | 4,509 | -% |
2023-09-12 | DAVIDSON KEMPNER CAPITAL MANAGEMENT LP | added | 133 | 6,612,240 | 18,768,600 | 0.48% |
2023-08-29 | EFG Asset Management (Americas) Corp. | sold off | -100 | -2,316,800 | - | -% |
2023-08-25 | Yarbrough Capital, LLC | unchanged | - | -117,919 | 228,767 | 0.01% |
2023-08-24 | ProVise Management Group, LLC | new | - | 619,354 | 619,354 | 0.06% |
2023-08-24 | Alberta Investment Management Corp | unchanged | - | -250,499 | 485,979 | -% |
2023-08-23 | Stonebridge Capital Advisors LLC | unchanged | - | -25,367 | 49,214 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
CTLT Alerts
Schedule 13G FIlings of Catalent
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 14, 2023 | t. rowe price investment management, inc. | 9.2% | 16,578,946 | SC 13G/A | |
| Feb 13, 2023 | capital world investors | 7.7% | 13,914,820 | SC 13G/A | |
| Feb 09, 2023 | janus henderson group plc | 4.6% | 8,216,242 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 10.88% | 19,588,103 | SC 13G/A | |
| Feb 07, 2023 | blackrock inc. | 7.7% | 13,788,094 | SC 13G/A | |
| Jan 27, 2023 | veritas asset management llp | 6.21% | 11,169,815 | SC 13G | |
| Feb 14, 2022 | price t rowe associates inc /md/ | 10.8% | 18,616,482 | SC 13G/A | |
| Feb 11, 2022 | capital world investors | 6.2% | 10,577,293 | SC 13G | |
| Feb 09, 2022 | vanguard group inc | 10.79% | 18,479,271 | SC 13G/A | |
| Feb 03, 2022 | blackrock inc. | 8.8% | 14,998,086 | SC 13G/A |
Recent SEC filings of Catalent
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 15, 2023 | 8-K | Current Report | |
| Sep 12, 2023 | 3 | Insider Trading | |
| Sep 12, 2023 | 4 | Insider Trading | |
| Sep 11, 2023 | 8-K | Current Report | |
| Sep 05, 2023 | 4 | Insider Trading | |
| Sep 01, 2023 | 4 | Insider Trading | |
| Aug 30, 2023 | 4 | Insider Trading | |
| Aug 30, 2023 | NT 10-K | NT 10-K | |
| Aug 30, 2023 | 4 | Insider Trading | |
| Aug 30, 2023 | 4 | Insider Trading |
CTLT Fair Value
Loading...
Peers (Alternatives to Catalent)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
LLY | 494.6B | 29.5B | -0.66% | 79.36% | 76.12 | 16.76 | 1.53% | 14.16% |
JNJ | 408.2B | 97.8B | -4.35% | -2.72% | 31.27 | 4.18 | 2.29% | -28.92% |
MRK | 272.8B | 58.3B | -4.37% | 23.96% | 17.88 | 4.63 | 2.00% | -81.24% |
PFE | 181.2B | 77.9B | -10.94% | -25.44% | 8.44 | 2.33 | -23.04% | -26.74% |
BMY | 150.1B | 45.2B | -5.70% | -15.91% | 23.72 | 3.25 | -4.15% | 20.34% |
| MID-CAP | ||||||||
RETA | 6.5B | - | 1.99% | 679.20% | -74.1 | 4.1K | -86.94% | 71.24% |
PRGO | 4.3B | 4.6B | -16.08% | -16.44% | -62.93 | 0.92 | 6.60% | 42.04% |
| SMALL-CAP | ||||||||
SUPN | 1.6B | 634.0M | -6.94% | -10.23% | 36.56 | 2.5 | 0.62% | -24.59% |
TLRY | 1.6B | 627.1M | -7.75% | -11.11% | -1.08 | 2.51 | -0.20% | -204.67% |
INVA | 858.4M | 244.3M | -1.05% | 13.25% | 4.35 | 3.51 | -39.50% | -4.99% |
CRON | 788.9M | 109.5M | 24.85% | -25.44% | -5.5 | 7.2 | -2.66% | -32.13% |
CGC | 489.9M | 453.3M | 136.46% | -66.34% | -0.4 | 1.08 | -16.04% | 55.90% |
ACRS | 471.3M | 31.2M | -3.91% | -52.16% | -4.48 | 15.12 | 407.54% | -26.47% |
OCUL | 255.1M | 54.6M | -17.22% | -39.02% | -2.81 | 4.67 | 9.39% | -179.16% |
ENDP | - | 2.2B | - | - | - | - | -22.39% | 63.59% |
Catalent News
Returns for CTLT
Cumulative Returns on CTLT
8.2%
7-Year Cumulative Returns
0.2%
5-Year Cumulative Returns
-17.7%
3-Year Cumulative Returns
Risks for CTLT
What is the probability of a big loss on CTLT?
75.4%
Probability that Catalent stock will be more than 20% underwater in next one year
65.8%
Probability that Catalent stock will be more than 30% underwater in next one year.
20.8%
Probability that Catalent stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does CTLT drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Catalent was unfortunately bought at previous high price.
Drawdowns
Financials for Catalent
Income Statement (Last 12 Months)(In Millions)
| Income Statement (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 | 2017Q4 |
| Revenue | -5.0% | 4,488 | 4,724 | 4,792 | 4,802 | 4,703 | 4,483 | 4,177 | 3,998 | 5,904 | 5,612 | 5,422 | 5,241 | 2,862 | 2,671 | 2,540 | 2,478 | 2,488 | 2,471 | 2,463 | 2,395 | 2,300 |
| Gross Profit | -16.0% | 1,280 | 1,523 | 1,541 | 1,614 | 1,591 | 1,534 | 1,427 | 1,352 | 1,248 | 1,120 | 1,055 | 983 | 905 | 865 | 834 | 782 | 775 | 761 | 753 | 734 | 710 |
| S&GA Expenses | -2.0% | 838 | 855 | 857 | 844 | 802 | 768 | 705 | 687 | 660 | 623 | 599 | 577 | 563 | 557 | 539 | 494 | 481 | 473 | 465 | 447 | 431 |
| EBITDA | -61.4% | 284 | 735 | 772 | 860 | 843 | 967 | 940 | 894 | 856 | 550 | 481 | 388 | 267 | 289 | - | - | - | - | - | - | - |
| EBITDA Margin | -59.3% | 0.06* | 0.16* | 0.16* | 0.18* | 0.18* | 0.22* | 0.23* | 0.22* | 0.23* | 0.16* | 0.15* | 0.13* | 0.09* | 0.11* | - | - | - | - | - | - | - |
| Interest Expenses | -12.5% | -162 | -144 | -129 | -123 | -123 | -117 | -111 | -110 | -99.40 | -106 | -115 | -126 | -136 | -128 | -119 | -110 | -113 | -115 | -111 | -104 | -96.70 |
| Earnings Before Taxes | -97.2% | 13.00 | 471 | 472 | 579 | 615 | 756 | 750 | 715 | 672 | 384 | 334 | 260 | 161 | 174 | 167 | 170 | 160 | 137 | 152 | 132 | 134 |
| EBT Margin | -95.6% | 0.00* | 0.10* | 0.10* | 0.13* | 0.13* | 0.17* | 0.18* | 0.18* | 0.18* | 0.11* | 0.10* | 0.08* | 0.06* | 0.06* | - | - | - | - | - | - | - |
| Net Income | -95.8% | 16.00 | 384 | 401 | 499 | 513 | 604 | 595 | 585 | 556 | 345 | 303 | 221 | 138 | 148 | 152 | 149 | 136 | 65.00 | 84.00 | 63.00 | 70.00 |
| Net Income Margin | -94.1% | 0.00* | 0.08* | 0.09* | 0.11* | 0.11* | 0.13* | 0.14* | 0.15* | 0.15* | 0.10* | 0.09* | 0.07* | 0.05* | 0.05* | - | - | - | - | - | - | - |
| Free Cashflow | -51.8% | -563 | -371 | -471 | -221 | -110 | -182 | -244 | -253 | -188 | -134 | 23.00 | -25.50 | -36.70 | 20.00 | - | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | -3.0% | 10,508 | 10,830 | 11,148 | 10,206 | 10,508 | 10,322 | 10,203 | 10,183 | 9,112 | 8,769 | 8,198 | 7,984 | 7,777 | 7,080 | 6,195 | 6,120 | 6,184 | 4,493 | 4,442 | 4,500 | 4,531 |
| Current Assets | 6.5% | 2,917 | 2,738 | 2,919 | 2,699 | 2,917 | 3,025 | 2,974 | 3,931 | 2,918 | 2,775 | 2,519 | 2,356 | 2,293 | 1,746 | 1,301 | 1,267 | 1,396 | 1,144 | 1,072 | 1,083 | 1,240 |
| Cash Equivalents | -100.0% | - | 252 | 442 | 281 | 449 | 786 | 849 | 1,969 | 896 | 988 | 833 | 1,007 | 953 | 608 | 189 | 243 | 345 | 228 | 208 | 266 | 410 |
| Inventory | -100.0% | - | 744 | 818 | 732 | 702 | 676 | 688 | 622 | 563 | 528 | 461 | 384 | 324 | 297 | 250 | 251 | 257 | 247 | 235 | 236 | 209 |
| Net PPE | -100.0% | - | 3,671 | 3,579 | 3,167 | 3,127 | 2,820 | 2,727 | 2,581 | 2,524 | 2,359 | 2,130 | 2,036 | 1,901 | 1,770 | 1,618 | 1,561 | 1,537 | 1,302 | 1,286 | 1,288 | 1,271 |
| Goodwill | -100.0% | - | 3,023 | 3,215 | 2,929 | 3,006 | 3,012 | 3,026 | 2,531 | 2,519 | 2,515 | 2,462 | 2,490 | 2,471 | 2,449 | 2,208 | 2,196 | 2,221 | 1,409 | 1,421 | 1,435 | 1,397 |
| Liabilities | -6.4% | 5,733 | 6,127 | 6,256 | 5,526 | 5,733 | 5,690 | 5,722 | 5,803 | 4,838 | 4,697 | 4,384 | 4,306 | 4,271 | 4,285 | 3,873 | 3,864 | 3,896 | - | - | - | 3,444 |
| Current Liabilities | -26.2% | 1,098 | 1,487 | 1,552 | 969 | 1,098 | 1,046 | 1,045 | 1,096 | 1,196 | 1,139 | 1,024 | 920 | 893 | 917 | 658 | 616 | 671 | 525 | 514 | 528 | 577 |
| Long Term Debt | -100.0% | - | 4,261 | 4,221 | 4,098 | 4,171 | 4,157 | 4,191 | 4,225 | 3,166 | 3,150 | 2,984 | 2,985 | 2,945 | 2,927 | 2,825 | 2,859 | 2,883 | 2,116 | 2,130 | 2,206 | 2,649 |
| Shareholder's Equity | 1.5% | 4,775 | 4,703 | 4,892 | 4,680 | 4,775 | 4,632 | 4,481 | 4,021 | 3,915 | 3,713 | 3,456 | 3,072 | 2,899 | 2,188 | 1,716 | 1,649 | 1,682 | 1,621 | 1,563 | 1,529 | 1,086 |
| Retained Earnings | 39.2% | 518 | 372 | 619 | 518 | 518 | 350 | 209 | 114 | 25.00 | -150 | -377 | -460 | -535 | -681 | -694 | -731 | -723 | -790 | -822 | -871 | -872 |
| Additional Paid-In Capital | -100.0% | - | 4,697 | 4,686 | 4,674 | 4,649 | 4,630 | 4,615 | 4,234 | 4,205 | 4,186 | 4,161 | 3,901 | 3,818 | 3,261 | 2,759 | 2,755 | 2,757 | 2,739 | 2,735 | 2,734 | 2,283 |
| Accumulated Depreciation | -100.0% | - | 1,540 | 1,465 | 1,358 | 1,347 | 1,308 | 1,215 | 1,215 | 1,179 | - | - | - | - | - | - | - | - | - | - | - | - |
| Shares Outstanding | -100.0% | - | 180 | 180 | 180 | 179 | 179 | 171 | 171 | 171 | 170 | 170 | 165 | 163 | 155 | 146 | 146 | 146 | 145 | 145 | 145 | 133 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 |
| Cashflow From Operations | -61.4% | 127 | 329 | 184 | 439 | 504 | 441 | 446 | 433 | 471 | 518 | 565 | 440 | 356 | 309 | 232 | 248 | 263 | 283 | 332 | 375 | 371 |
| Share Based Compensation | -7.8% | 47.00 | 51.00 | 52.00 | 54.00 | 55.00 | 60.00 | 68.00 | 51.00 | 51.00 | - | - | 48.00 | - | - | - | 33.00 | - | - | 20.00 | 27.00 | 26.00 |
| Cashflow From Investing | 6.2% | -1,228 | -1,309 | -1,833 | -1,884 | -1,703 | -1,594 | -665 | -649 | -598 | -981 | -893 | -827 | -1,917 | -1,500 | -1,429 | -1,510 | -316 | -302 | -1,042 | -919 | -912 |
| Cashflow From Financing | -3.7% | 573 | 595 | 23.00 | 1,031 | 1,013 | 1,182 | 1,174 | 142 | 490 | 1,097 | 1,088 | 1,002 | 1,954 | 1,173 | 1,184 | 1,201 | -88.00 | -87.10 | 387 | 669 | 668 |
| Buy Backs | - | - | - | - | - | - | - | - | - | - | 768 | 770 | - | 659 | -0.27 | -0.27 | - | 445 | 446 | 446 | 278 | 278 |
CTLT Income Statement
2022-06-30Consolidated Statements of Operations - USD ($) | 12 Months Ended | ||
|---|---|---|---|
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2020 | |
| Income Statement [Abstract] | |||
| Revenues | $ 4,802,000,000 | $ 3,998,000,000 | $ 3,094,000,000 |
| Cost of Goods and Services Sold | 3,188,000,000 | 2,646,000,000 | 2,111,000,000 |
| Gross Profit | 1,614,000,000 | 1,352,000,000 | 983,000,000 |
| Selling, General and Administrative Expense | 844,000,000 | 687,000,000 | 577,000,000 |
| Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal | 1,000,000 | 182,000,000 | (1,000,000) |
| Other Cost and Expense, Operating | 41,000,000 | 19,000,000 | 11,000,000 |
| Operating Income (Loss) | 730,000,000 | 828,000,000 | 394,000,000 |
| Interest Income (Expense), Net | (123,000,000) | (110,000,000) | (126,000,000) |
| Nonoperating Income (Expense) | (28,000,000) | (3,000,000) | (8,000,000) |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | 579,000,000 | 715,000,000 | 260,000,000 |
| Income Tax Expense (Benefit) | 80,000,000 | 130,000,000 | 39,000,000 |
| Net Income (Loss) Attributable to Parent | 499,000,000 | 585,000,000 | 221,000,000 |
| Participating Securities, Distributed and Undistributed Earnings (Loss), Basic | 16,000,000 | 56,000,000 | 48,000,000 |
| Net Income (Loss) Available to Common Stockholders, Basic | $ 483,000,000 | $ 529,000,000 | $ 173,000,000 |
| Earnings Per Share, Basic | $ 2.74 | $ 3.15 | $ 1.16 |
| Earnings Per Share, Diluted | $ 2.73 | $ 3.11 | $ 1.14 |
CTLT Balance Sheet
2022-06-30Consolidated Balance Sheet - USD ($) | Jun. 30, 2022 | Jun. 30, 2021 |
|---|---|---|
| Statement of Financial Position [Abstract] | ||
| Cash and Cash Equivalents, at Carrying Value | $ 449,000,000 | $ 896,000,000 |
| Accounts Receivable, after Allowance for Credit Loss, Current | 1,051,000,000 | 1,012,000,000 |
| Inventory, Net | 702,000,000 | 563,000,000 |
| Prepaid Expense and Other Assets, Current | 626,000,000 | 376,000,000 |
| Marketable Securities | 89,000,000 | 71,000,000 |
| Assets, Current | 2,917,000,000 | 2,918,000,000 |
| Property, Plant and Equipment, Net | 3,127,000,000 | 2,524,000,000 |
| Goodwill | 3,006,000,000 | 2,519,000,000 |
| Intangible Assets, Net (Excluding Goodwill) | 1,060,000,000 | 817,000,000 |
| Deferred Tax Assets, Deferred Income | 49,000,000 | 66,000,000 |
| Other Assets, Noncurrent | 349,000,000 | 268,000,000 |
| Assets | 10,508,000,000 | 9,112,000,000 |
| Debt, Current | 31,000,000 | 75,000,000 |
| Accounts Payable, Current | 421,000,000 | 385,000,000 |
| Other Accrued Liabilities, Current | 646,000,000 | 736,000,000 |
| Liabilities, Current | 1,098,000,000 | 1,196,000,000 |
| Long-Term Debt and Lease Obligation | 4,171,000,000 | 3,166,000,000 |
| Liability, Defined Benefit Pension Plan, Noncurrent | 103,000,000 | 137,000,000 |
| Deferred Tax Liabilities, Tax Deferred Income | 197,000,000 | 164,000,000 |
| Other Liabilities, Noncurrent | 164,000,000 | 175,000,000 |
| Liabilities | 5,733,000,000 | 4,838,000,000 |
| Common Stock, Value, Outstanding | 2,000,000 | 2,000,000 |
| Preferred Stock, Value, Outstanding | 0 | |
| Additional Paid in Capital, Common Stock | 4,649,000,000 | 4,205,000,000 |
| Retained Earnings (Accumulated Deficit) | 518,000,000 | 25,000,000 |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | (394,000,000) | (317,000,000) |
| Equity, Attributable to Parent | 4,775,000,000 | 3,915,000,000 |
| Liabilities and Equity | 10,508,000,000 | 9,112,000,000 |
| Redeemable Preferred Stock Outstandings | $ 0 | $ 359,000,000 |
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.